Stay ahead of the curve and gain valuable knowledge that can help bring a market access mindset to your commercial and development strategies.
As we start the new year, it is important to make sure our strategies reflect trends and changes influencing the healthcare landscape. Since August of 2022, when the President signed the Inflation Reduction Act (IRA), the new authority granted to CMS allowing Medicare to negotiate the price...
Happy New Year from A3Access! Are you resolved to address your market access issues this year? The calendar has turned, and we are just a few days into the New Year...
Your approach to distribution can have a profound impact on a medicine’s success. Taking a strategic approach can result in an optimal patient experience as well as deliver financial benefits...
In our last post, we spoke about the critical importance of Payer engagement. A question we often hear from clients on that topic is, “When should that process start?”...
With an ever-increasing number of complex, game changing medicines coming to market, there has never been a more important time for effective engagement with both private and public payers...
During our tenure as biopharma executives, and now as advisors, we have observed, first-hand, very common missteps organizations make when building and executing their market access strategies...
With an ever-increasing number of complex, game changing medicines coming to market, there has never been a more important time for effective engagement with both private and public payers. The pace of innovation is...
We believe there is still an opportunity for first-in-class and best in class medicines to achieve premium pricing and commercial success. But… the margin for error is getting slimmer and slimmer...